In the fight against the corona pandemic, the focus is on vaccines. The search for drugs against Covid-19 is receiving less attention. But despite the approval of several vaccines, the disease is far from gone. What about the medicines – an overview.
The federal government apparently has great hopes for so-called antibody agents for Covid 19 diseases. For Germany she bought 200,000 cans for 400 million euros. According to the Federal Ministry of Health, these are the drugs REGN-COV2 and Bamlavinimab. Both agents have already received emergency approval in the USA, but have not yet been approved in the EU. REGN-COV2 gained worldwide notoriety last October after the then US President Trump was treated with this antibody cocktail. We have compiled detailed information about the antibody agents here.
The re are also numerous other approaches to treating Covid 19 patients. Many drugs that had actually been developed for other diseases were tried. It can take years for completely new drugs to be developed and approved. However, there were also setbacks in the treatment attempts. High hopes were placed in the drug Remdesivir, which was originally developed against hepatitis C and Ebola. Ultimately, however, studies showed that it only had an effect on the course of the disease in the case of infections with the coronavirus in limited cases. Further connections are still being explored.
German company relies on a “gatekeeper” preparation
The drug is called FYB207 and, according to the company, it uses the property of coronaviruses to penetrate or spread further via a receptor on the surface of human body cells. This receptor is blocked by the agent – and with it the gateway into the organism. It is a so-called antibody fusion protein that could be used and that, according to research results, binds effectively to Sars coronaviruses.
The chairman of Formycon, Brockmeyer, sees a chance, especially for seriously ill Covid-19 patients, to experience a milder course. “This means that (these) patients also have a treatment option,” Brockmeyer said in an interview with tagesschau.de. “We block the entry gate that the virus uses to penetrate the cells. This offers maximum protection against mutations. This is how we also prevent future coronavirus epidemics,” emphasizes Brockmeyer.
However, it may still take some time before the drug is ready for the market: the company does not expect approval to be granted for at least one year.
Influenza medication is supposed to stop the transmission of coronaviruses
The research team from Atlanta has published a study in the journal Nature Microbiology that shows in animal experiments that the drug slows down the transmission of coronaviruses within 24 hours.
The animals were given molnupiravir twice a day – as a result, the Sars-CoV-2 exposure in the upper airways was significantly reduced and the spread to untreated contact animals was prevented. If it turns out that the effectiveness in humans is similar, then Covid 19 sufferers would no longer be contagious within 24 hours of taking the drug.
Money for more research
In addition to the use of vaccines, the federal government is also using drugs for Covid 19 patients to combat pandemics. It is funding both the development of drugs and their clinical testing until the end of 2023.
The guideline on the inpatient treatment of COVID-19 patients, which was compiled by several specialist societies, is aimed primarily at professionals.
Further articles on the coronavirus
We have created a news blog. In view of the large amount of information, this provides an overview of the most important current developments.
+ Extended lockdown: what rules apply and what opening perspectives are there? (As of February 17th)
+ New rules: How the federal states implement the lockdown resolutions (as of February 17)
+ Border controls: what to watch out for (as of February 15)
Test and protection
The vaccination ordinance: who will be vaccinated first, who later? (As of: February 17th)
+ Dates: how, when and where can I get vaccinated? (Status: February 12th)
+ Vaccinations: What is known about the side effects of the corona vaccine (as of February 16)
+ Astrazeneca vaccine: reports of side effects and acceptance problems – experts disagree (17.02.)
+ Protection: So it is about the development of vaccines against the coronavirus (as of February 15)
+ Change of strategy: are rapid tests the breakthrough in fighting pandemics? (As of February 16)
+ Sick people: New insights into the search for drugs (as of January 30)
Treatment: How does an antibody drug work and when is it useful? (As of January 25th)
+ Economy: How the world of work deals with the number of infections (as of February 16)
Contagion and Transmission
+ Virus variants: how dangerous are the new mutations of the coronavirus? (As of: February 17th)
+ Opponents of infection protection measures: What AfD and lateral thinkers have to do with the spread of the coronavirus in Germany (as of 02/09)
+ Transfer: What role do aerosols play (as of January 22)
+ Excess mortality: how deadly is the coronavirus really? (Status: 05.02.)
+ Travel warning:
The current list of risk areas (as of February 17th)
You can also find the Dlf news on Twitter at: @DLFNews.